China Law & Practice

Follow us:

profile

China Law & Practice

CLP_editorial

CLP_editorial profile

RT @bobdavis187: 4 Things We Learned from China’s 4th Plenum | The Diplomat. Interesting take on a fuzzy document. http://t.co/AnUHqvJ2KO

Oct 24 2014 06:29 ·  reply ·  retweet ·  favourite
CLP_editorial profile

Legislation roundup: Delisting, trademark trials and online insurance: http://t.co/A1ftgjBKFm

Oct 24 2014 06:26 ·  reply ·  retweet ·  favourite
CLP_editorial profile

In the news: Apple talks data security, Costco partners with Alibaba and MOFCOM merger reviews: http://t.co/fAOypuGY8F

Oct 24 2014 06:26 ·  reply ·  retweet ·  favourite
Magazine

Change font size: Switch to default font size Switch to medium font size Switch to large font size

Patent System to Catch Up with Pharmaceutical Industry Expansion

The pharmaceutical industry in China has been expanding in recent years as the government strives to invent its own drugs and brands. However, the prevalence of counterfeit and generic drugs still remains a significant IP issue. The patent system needs further development before it will be able to properly protect patent holders.

Issue: June 2008

Keywords (click to search): Pharmaceutical drugs counterfeit generic

  The execution of Zheng Xiaoyu for corruption and dereliction of duty made headlines last year. As former director of Chinese watchdog the State Food and Drug Administration (SFDA), Zheng's death sentence reflects the PRC government's determination to protect consumers. For the pharmaceutical industry, the execution represented a step in the right direction. This sector has been widely criticized due to the prevalence of fake drugs and the lack of intellectual property (IP) protection from the government. The 2003 SARS attack, worldwide anger over deaths caused by the exportation of contaminated food and fake drugs, and Zheng's approval of unsafe drugs in violation of new rules all exposed China's lack of enforcement in the health care system. The Zheng scandal alerted the government to the need to reform the nation's pharmaceutical image by promulgating new measures and regulations. At the opening of the National People's Congress Premier Wen Jiabao emphasized the...


Register with China Law & Practice to unlock our premium content for the next 14 days.

**Full text translations are only available for individual purchase or as part of a subscription.
**